CSL LIMITED (CSL)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
CSL - CSL LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 3.28
Index: ASX20 | ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 3.28
CSL is a global biotechnology company that researches, develops, manufactures and markets products for the treatment of human diseases. With a market cap of over $138bn it is one of Australia's top three largest index weights. The former Commonwealth Serum Laboratory listed in June 1994 and has generated an average annual return of 28% since (up until mid-2020). CSL is the world's largest collector of plasma and the second largest producer of vaccines.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$279.58
14 May |
-0.340 OPEN $278.87 |
-0.12% HIGH $282.07 |
493,675 LOW $278.94 |
TARGET | |||||
|
|||||
Franking for last dividend paid out: 0% |
OTHER COMPANIES IN THE SAME SECTOR | |||
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY24 Forecast |
FY25 Forecast |
---|---|---|
EPS (cps) | 938.1 | xxx |
DPS (cps) | 407.9 | xxx |
EPS Growth | N/A | xxx |
DPS Growth | N/A | xxx |
PE Ratio | 30.2 | xxx |
Dividend Yield | 1.4% | xxx |
Div Pay Ratio(%) | 43.5% | xxx |
All estimates have been converted into AUD by FNArena at present FX values.
Last ex-div: 11/03 - ex-div 182.57c (franking 0%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | 691.9 |
DPS All | xxx | xxx | xxx | xxx | xxx | 362.9 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 19,585.3 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 4,916.4 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 3,866.8 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 17.03 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | 14.86 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | 9.64 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | 6.98 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | 14.86 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 10.85 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 428.2 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 1,585 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 16,784 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 18,369 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 12,137 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 2,326 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 5.64 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 2,515.4 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 12.84 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 10,120 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 5,105 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 1,836 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 260 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
CSL STOCK CHART
FNArena News on CSL
1 |
Rudi’s View: Arcadium Lithium, Goodman Group, Paladin, Pexa & Treasury WineMay 09 2024 - Rudi's View |
2 |
April In Review: The Bond Market RoaredMay 06 2024 - Australia |
3 |
Rudi’s View: Quality Reigns, And How To Identify ItMay 01 2024 - Rudi's View |
4 |
Rudi’s View: A Market Narrative DelayedApr 24 2024 - Rudi's View |
5 |
Rudi’s View: Shaky Sentiment Ahead Of Corporate UpdatesApr 17 2024 - Rudi's View |
Latest Pharmaceuticals & Biotech/Lifesciences News
1 |
Dr Boreham’s Crucible: InvionMay 13 2024 - Small Caps |
2 |
Dr Boreham’s Crucible: Race OncologyApr 09 2024 - Small Caps |
3 |
The Power Of New Weight-Loss DrugsApr 03 2024 - International |
4 |
Dr Boreham’s Crucible: Neuren PharmaceuticalsMar 11 2024 - Small Caps |
5 |
Spotlight On ASX-Listed Cannabis CompaniesJan 31 2024 - Small Caps |
6 |
Transformational Trial Results For Neuren PharmaceuticalsDec 20 2023 - Small Caps |
7 |
Dr Boreham’s Crucible: ImugeneDec 11 2023 - Small Caps |
8 |
Dr Boreham’s Crucible: PYC TherapeuticsNov 22 2023 - Small Caps |
9 |
Dr Boreham’s Crucible: Paradigm BiopharmaceuticalsNov 06 2023 - Small Caps |
10 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |